Skip to main content
Premium Trial:

Request an Annual Quote

Life Insurer GWG Acquires Rights to Epigenetic Mortality Predictor Tech

NEW YORK (GenomeWeb) – GWG Holdings, the parent company of life insurance firm GWG Life, announced today that it has exclusively licensed technology from the University of California, Los Angeles, related to the use of epigenetic markers to predict life expectancy.

The technology is based on the work of UCLA's Steve Horvath, who has shown that DNA methylation age, measured in blood, could predict all-cause mortality later in life, independent of health status, lifestyle, and known genetic factors.

In November, GWG optioned the technology — which measures the methylation of certain CpG sites as markers of biological aging — so GWG Life could develop it as a method for generating more accurate life expectancy projections. Earlier this year, GWG Life began collecting and analyzing epigenetic data from policyholders selling their life insurance.

GWG has now exercised its option, picking up the exclusive rights to the technology for use in life insurance and related industries. Additional terms of the deal were not disclosed.

"Even though we've only scratched the surface, epigenetics are already showing much more promise for assessing human health than merely looking at the genetic sequence," Brian Chen, vice president of research and analytics at GWG Life and Horvath collaborator, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.